Table 1 Clinical and laboratory features of MM patients treated with lenalidomide
Clinical feature | Total (n = 50) | IKZF1 high expression (n = 36) | IKZF1 low expression (n = 14) | P value | IKZF3 high expression (n = 29) | IKZF3 low expression (n = 21) | P value |
|---|---|---|---|---|---|---|---|
Sex (M/F) | 31/19 | 23/13 | 8/6 | 0.6590 | 19/10 | 12/9 | 0.5471 |
Age (year), median (range) | 59(41–75) | 57 (41–73) | 59 (45–75) | 0.6416 | 57 (41–69) | 59 (44–75) | 0.3105 |
International staging system, no. (%) | 0.1785 | 0.1448 | |||||
I | 24 (48) | 14 (38.89) | 10 (71.43) | 11 (37.93) | 13 (61.90) | ||
Il | 18 (36) | 14 (38.89) | 4 (28.57) | 11 (37.93) | 7 (33.33) | ||
III | 5 (10) | 5 (13.89) | 0 (0) | 5 (17.24) | 0 (0) | ||
NA | 3 (6) | 3 (8.33) | 0 (0) | 2 (6.90) | 1 (4.76) | ||
Hemoglobin concentration (g/L), median (range) | 105 (76–147) | 106 (76–147) | 103 (86–132) | 0.6027 | 104 (76–147) | 107 (85–141) | 0.3121 |
Calcium (mmol/L), median (range) | 2.25 (1.98–2.57) | 2.26 (1.98–2.57) | 2.23 (2–2.55) | 0.8162 | 2.25 (1.98–2.57) | 2.25 (2–2.55) | 0.7160 |
Creatinine (μmol/L), median (range) | 76 (32–360) | 86 (40–360) | 67.58 (32–126) | 0.0569 | 88 (57–360) | 66 (32–126) | 0.0072 |
Having lytic lesions, number of patients (%) | 27 (54) | 18 (50) | 9 (64.29) | 0.3628 | 12 (41.38) | 15 (71.43) | 0.0354 |
B2-microglobulin (mg/L) | 3.08 (0.51–16.76) | 3.50 (0.51–16.76) | 2.96 (1.35–5.16) | 0.5817 | 3.62 (0.51–16.76) | 2.82 (1.07–5.16) | 0.1293 |
Albumin (gr/L) | 40.5 (28–47) | 41 (28–47) | 39 (29–44) | 0.6151 | 41 (28–47) | 40 (29–44) | 0.9078 |
Prior therapies, no. (%) | |||||||
≥3 | 23 (46) | 15 (41.67) | 8 (57.14) | 0.3242 | 12 (41.38) | 11 (52.38) | 0.4411 |
Thalidomide | 29 (58) | 22 (61.11) | 7 (50) | 0.4748 | 15 (51.72) | 14 (66.67) | 0.2907 |
Bortezomib | 21 (42) | 14 (38.89) | 7 (50) | 0.4748 | 12 (41.38) | 9(42.86) | 0.9168 |
ASCT | 40 (80) | 31 (86.11) | 9 (64.29) | 0.1180 | 25 (86.21) | 15 (71.43) | 0.2859 |
Response to lenalidomide plus dexamethasone, no. (%) | |||||||
Responsive | 41 (82) | 32 (88.89) | 9 (64.29) | 0.094 | 28 (96.55) | 13 (61.90) | 0.0025 |
Non-responsive | 9 (18) | 4 (11.11) | 5 (35.71) | 1 (3.45) | 8 (38.1) | ||
Cytogenetics, no. (%) | |||||||
del (13q) | 1.0000 | 0.7243 | |||||
Positive | 13 (26) | 9 (25) | 4 (28.57) | 7 (24.14) | 6 (28.57) | ||
Negative | 37 (74) | 27 (75) | 10 (71.43) | 22 (75.86) | 15 (71.43) | ||
del (17p) | 0.1966 | 0.2552 | |||||
Positive | 8 (16) | 4 (11.11) | 4 (28.57) | 3 (10.34) | 5 (23.81) | ||
Negative | 42 (84) | 32 (89) | 10 (71.43) | 26 (89.66) | 16 (76.19) | ||
t(4;14) | 1.0000 | 0.7163 | |||||
Positive | 9 (18) | 7 (19.44) | 2 (14.29) | 6 (20.69) | 3 (14.29) | ||
Negative | 41 (82) | 29 (80.56) | 12 (85.71) | 23 (79.31) | 18(85.71) | ||
amp(1q21) | 0.1228 | 0.1283 | |||||
Positive | 20 (40) | 12 (33.33) | 8 (57.14) | 9 (31.03) | 11 (52.38) | ||
Negative | 30 (60) | 24 (66.67) | 6 (42.86) | 20(68.97) | 10 (47.62) | ||